PPCB

Propanc is a preclinical Australian pharma shell with no product and no revenue in any year shown (FY2021–FY2025 all report revenue as —). The entire enterprise runs on $224K of annual R&D and burns cash from a principal office it leases from the CEO's own family entity (North Horizon Pty Ltd) for ~$2,127/month — this is a related-party micro-operation, not a scaled drug developer. The MD&A's own stated risk list is telling: 'our ability to raise capital is necessary to sustain our anticipated operations,' 'our ability to generate sufficient cash to survive,' and it openly concedes it issued 'penny stock' — this is a company whose forward existence depends on selling more shares.

The FY2025 headline loss of -$58.9M (EPS -$14.85, ROE -423.7%) is wildly out of proportion to a business with only -$405K of operating cash outflow. That gap means the reported loss is overwhelmingly non-cash — almost certainly derivative/financing charges tied to convertible/toxic financing, not operations. Meanwhile shares outstanding 'fell' 98.1% to 12.8M, the signature of a large reverse split, and the accumulated deficit sits at -$126M against $13.9M of equity. The optical improvements (equity +468%, assets +27,028%, EPS +99%) are artifacts of the split and financing mechanics resetting off a near-zero base, not a turnaround.